Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Fortress Biotech to Participate in the 2nd Annual Winter Wonderland Best Ideas Virtual Investor Conference

Feb 07, 2022

Checkpoint Therapeutics to Participate in the B. Riley Securities’ Virtual Oncology Conference

Jan 25, 2022

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Jan 25, 2022

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients

Jan 24, 2022

Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.

Jan 13, 2022

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Jan 07, 2022

Fortress Biotech to Participate in the H.C. Wainwright BioConnect Virtual Conference

Jan 06, 2022

Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences

Jan 05, 2022
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap